Advancing Novel Biotherapeutics Since 1995®

Investor Relations

Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory indications. We utilize our proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Click here to learn more.

More »Stock Quote

DYAX (Common Stock)
Exchange NASDAQ (US Dollars)
Price $13.27
Change (%) 0.05 (0.38)%
Volume 889,000
Data as of Nov 21, 2014 4:00 PM ET
Delayed at least 20 minutes. Provided by eSignal.
Refresh Quote

More »Recent Releases

Date Title
Nov 18, 2014 Dyax Corp. Recognized as a "Top Place to Work" by The Boston Globe
Nov 3, 2014 Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Oct 28, 2014 Dyax Corp. Announces Third Quarter 2014 Financial Results
Oct 14, 2014 Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast

More »Calendar of Events

Details on upcoming events are not yet available.

More » Event Archives

Oct 28, 2014 Dyax Corp. 3Q 2014 Earnings Call
Oct 1, 2014 Leerink Partners Rare Disease Roundtable
Jul 29, 2014 Dyax Corp. 2Q 2014 Earnings Call
Jun 17, 2014 2014 Wells Fargo Healthcare Conference

Featured Financial Reports

Filing Date Title Type Size
Nov 3, 2014 10-Q View HTML View PDF 530.9 KB Add to Briefcase
Dec 31, 2013 2013 Annual Report PDF  508.9 KB Add to Briefcase
Add to Briefcase = add file to Briefcase

You are now leaving Dyax.com.

The web site you are about to visit is . It is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?